Pharmacy and therapeutics committee

Pharmacy and Therapeutics Committee
Meeting of September 13, 2005
Kellogg Center, Michigan State University
MEETING MINUTES
I. Welcome and Introductions, and Approval of June 7, 2005 Meeting Minutes
The meeting was called to order at 6:00PM by Richard Slaughter, Chair. In attendance
were Richard Slaughter, MSc., D.VanLoo, PharmD., M. Robins DO, G. Perri, MD,
Jonathan Arend, PharmD, Khan J. Nedd MD, Paul Dake MD., Ronald Bradley DO, and.
J. Fiechtner, MD from the Committee .The chair welcomed Neil B.Dorfman Pharm.D.
and Erin E. Inman, Pharm.D. to the Committee, pursuant to their recent appointments by
the Governor. Also attending were A. Paul, RPH.,D.Tatum RPH, J. Coleman, Medicaid
Policy, M. Sandusky, RPh.,G.Baker, MD, D. Quillan, Pharmacy Analyst, and Trish
O’Keefe, R.N. Pharmacy Manager.
The Minutes of the June 7, 2005 Meeting as posted were approved.
II. Public Comment:
Sheila Sprague, Dr.Ifkatar Amid, AstraZeneca, Nexium® Richard Fiscella, PharmD Allergan, , Univ Illinois,Zymar®, Elestat® Dr. Gary Ziegler, Family Physician, Kalkaska MI, Avandamet® Todd Lacksonen,Dr.Theofilus Glover, TAP, Prevacid® Melissa Longstreet Kay, Sepracor, Dr. Goetting, Kalamazoo, Lunesta® Laura Macione, RPh, Lilly, Humalog® and Humalog 75/25® Jay Gandhi, PharmD Sanofi-Aventis, Lantus®, Anzemet® Greg Katz, MD, Patanol®, Jayne Weiss, MD, WSU, Vigamox® R. Detloff,PharmD,Dr.Howard Bockrader, Pfizer, Lyrica® Catherine Freiman, PhD, Novartis, Focalin XR® Suzanne Rivkin, PharmD, Santarus, Zegerid® III. New Drugs

Following discussion, the Committee made the following recommendations:
Symlin® will be added to the Michigan Pharmaceutical Product List (MPPL),
and will be added as a new class, “Amylin analogs”, to the Preferred Drug List
(PDL)
Zylet® will be added to the MPPL
Lyrica® will be added to the MPPL, with a quantity limit of 600mg per day
Lunesta® will be added to the MPPL and to the PDL class of “Sedative
Hypnotics Non Barbiturates” with prior authorization required.
Revatio® will be added to the MPPL with prior authorization required. In
addition, editing will be constructed to eliminate any concomitant prescriptions
for Viagra®, Levitra® or Cialis® with Revatio®.
Aptivus® will be added to the MPPL.
IV. Line Extensions

Following discussion, the Committee made the following recommendations:
Vopac® will be added to the PDL in “Narcotics-Short and Intermediate Acting”
class requiring prior authorization.
Combunox® will be added to the PDL in “Narcotics-Short and Intermediate
Acting” class, requiring prior authorization.
Zegerid® will be added to the PDL category of “Proton Pump Inhibitors” with
prior authorization.
Xopenex HFA® will be added to the PDL category of “Beta Adrenergics-Short
Acting” with prior authorization
Focalin XR® will be added to the PDL category of “Drugs For ADHD” without
prior authorization.
V. Review of PDL Classes
The classes of drugs on the PDL under the headings of “Gastrointestinal” and
“Diabetes” were discussed, following summaries of the workgroups’ analyses by
the respective chairs, Jonathon Arend, PharmD, for the GI group, and Paul Dake,
MD for the diabetes group. The committee voted to make the following changes
to these existing PDL drug classes:
Humalog® will no longer require prior authorization
“Biguanides-combination”: Avandamet® will no longer require prior
authorization
“Proton Pump Inhibitors”: Prilosec OTC® will no longer require prior
authorization
The other drugs in these classes will remain unchanged. The clinical edit for high
dose PPIs prescribed for more than 102 days was recommended to remain in
place.
VI. Review of Candidates for PDL Listing J. Fiechtner, MD presented information on the category of drugs termed
biological immunnomodulators, used to treat arthritic conditions. He discussed
Humira®, Enbrel®, and Kineret®.
Following this, the Committee voted to create a new PDL class, “Biological
Immunomodulators”, and to have Enbrel® and Humira® available without
prior authorization, and to require prior authorization for Kineret®.
G. Perri,MD discussed three classes of ophthalmic drugs, antihistamines, mast
cell stabilizers and fluoroquinolone antibiotics.
Following this, the Committee voted to add the following to the PDL:
A new class of “Ophthalmic Antihistamines” will be added: Elestat® and
Zaditor® will be available without prior authorization, and Emadine®,
Livostin®, Optivar®, and Patanol® will require prior authorization.
A new class of “Ophthalmic Mast Cell Stabilizers” will be added; Alocril® and
Cromolyn sodium ophthalmic will be available without prior authorization, and
Alamast®, Alomide®, Crolom® and Opticrom® will require prior
authorization.
A new class of “Ophthalmic Fluoroquinolones” will be added: Ciprofloxacin
and Vigamox® will be available without prior authorization, and Ciloxin®,
Ocuflox® ofloxacin, Quixin® and Zymar® will require prior authorization.
All the ophthalmic drug classes of the PDL will be combined under a new
heading.
VII. Workgroups for December Meeting ( Scheduled for Tuesday, December 6, 2005
at 6PM at the Kellogg Center)
R. Bradley, DO will be chair of the group reviewing the “Central Nervous
System” drug classes in the PDL, and J. Fiechtner, MD will chair the workgroup
on the “Analgesics” drug classes.
VIII. Public Comment Format. The Committee discussed making changes to the way public comment is presented to the group at the meetings. Several ideas were reviewed, and the committee reached consensus on the following plan: 30 minutes at the beginning of the meeting will be allowed for persons wishing to speak on the new drugs identified for review at that evening’s meeting. That means six speakers (or multiple speakers from a pharmaceutical company) would have five minutes each maximum; if more speakers sign up according to the committee rules, the maximum speaking time will be reduced to maintain a 30 minute maximum. At the end of the meeting, 30 minutes will be allowed for comment on the PDL classes to be reviewed at the next scheduled meeting. Again, the time per speaker would be adjusted as described above. In addition, the workgroup recommendations will be posted on the web site approximately one week before the meeting.

Source: https://michigan.fhsc.com/Downloads/PTMinutes20050913.pdf